Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX RELEASE
31 July 2023
JUNE 2023 QUARTERLY ACTIVITIES REPORT
Key Highlights
•
Top-line PARA_OA_008 Six-month Data Release: in April Paradigm reported exciting
novel 6-month data from the exploratory phase 2 study investigating the disease
modifying and clinical effects of injectable pentosan polysulfate sodium (iPPS)
compared to placebo in 61 subjects with knee osteoarthritis (OA). Six-month data
reported that participants receiving iPPS treatment demonstrated improvement in
cartilage loss, reductions in bone marrow lesions, and reductions in marginal
osteophytes as measured by MRI compared to placebo. The disease modifying OA drug
(DMOAD) potential for iPPS in knee OA treatment was also supported by changes and
trends in four key cartilage biomarkers (ARGS, COMP, C2C, and CTX-II) at six months.
•
Canine Model of Naturally Occurring OA: iPPS demonstrated durable improvements
in pain, joint function, and cartilage volume in canine osteoarthritis model at a 3-year
human-equivalent time point.
•
MPS I Positive Top-line Phase 2 Results: Primary and secondary endpoints were
attained in this open-label study of the rare disease MPS I. iPPS was well tolerated with
no serious adverse events reported out to 73 weeks. In the study, MPS I patients
experienced meaningful improvements in pain, function, and activities of daily living
and an overall improvement in quality of life.
•
MPS VI Study Completes Enrolment: Paradigm’s phase 2 MPS VI clinical trial based in
Brazil completed participant enrolment in April. The placebo-controlled, doubleblinded, randomised, 24-week phase 2 study compares iPPS to placebo in 13
participants with the ultra-rare disease MPS VI.
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) (“Paradigm” or “the Company”) is pleased to
provide its quarterly update for the three months ended 30 June 2023 to accompany its Appendix
4C cash flow report for the period.
•
Cash balance as of 30 June 2023 was $56.38m (on 31 March 2023 it was $73.2m).
•
Research and development expenditure for the quarter was $16.15m compared to the
previous quarter of $8.95m. The spend in Q4 FY23 is related to ongoing subject
recruitment initiatives and new site identification and activation for the PARA_OA_002
study, as well as biomarker and MRI analysis for the PARA_OA_008 phase 2 clinical trial
and the canine model of naturally occurring OA. The spend also included data review and
analysis for the MPS I study and site operations for the MPS VI phase 2 study, and an
ongoing New Drug Application (NDA) enabling nonclinical studies relating to our MPS and
OA clinical programs. The quarter also saw payments related to continuing activities
described in the outlook below.
•
The anticipated spend for the September 2023 quarter is expected to be at similar levels
to the June 2023 quarter as the company continues to run several pivotal studies.
•
In accordance with Listing Rule 4.7C.3 and as noted in item 6 of the Appendix 4C Cashflow
Statement, payments to related parties and their associates during the quarter ended 30
June 2023 were fees of $73K, which includes $66K for payment of Director fees, and $6K
for legal fees to BioMeltzer (a company related to Amos Meltzer).
QUARTERLY ACTIVITIES & OUTLOOK
Paradigm is pleased to provide an update on continuing activities.
PARA_OA_002 Phase 3 Clinical Trial
The June quarter saw considerable progress in the Phase 3 clinical program for OA. Paradigm
achieved the target of 120 clinical trial site activations to support the recruitment initiatives
undertaken by the Company. The PARA_OA_002 clinical trial has activated sites across seven
countries comprising Australia, the US and Canada in North America, and the UK, Belgium, Poland,
and Czechia in the EU. As Paradigm has reached its target for site activation and these clinical trial
sites have become familiar with the study design, Paradigm has been able to increase the number
of participants directed to these sites through the utilisation of diverse recruitment initiatives.
During the quarter, the independent data monitoring committee (DMC) conducted a second
formal safety review of the PARA_OA_002 clinical trial with the recommendation that the trial
proceed without modification.
To facilitate current and potential trial participants, Paradigm launched a new clinical trials website
in May called Hope4OA.com. The website is designed for ease of use where potential participants
can discover trial details and find answers to commonly asked questions. If interested, they are
invited to complete an online questionnaire to determine their eligibility as a potential trial
participant. The website hosts helpful explanations and instructional videos about clinical trials in
general, as well as providing links to patient support and further information.
Canine Naturally Occurring OA Model
Top-line data from the final cohort of dogs at week 26 was reported in June. The canine model of
naturally occurring OA was designed to gather further preclinical proof-of-concept and
translational data to determine the long-term effects of iPPS out to an approximate equivalent of
3 years in humans. These durable effects of iPPS out to at least 26 weeks in dogs support the
findings from the recently reported phase 2 PARA_OA_008 Day 168 clinical data.
The key data reported from this study at week 8 and 26, demonstrated iPPS:
•
•
Reduces pain at week 8 and week 26 in osteoarthritic dogs with meaningful effect size,
Improves joint function at week 8 and week 26 in osteoarthritic dogs with meaningful
effect size,
•
•
Inhibits OA disease progression by stabilising cartilage volume changes at week 8 and
week 26 in the stifle joints (knee equivalent) of osteoarthritic dogs; and
Favourably regulates serum levels of the biomarkers CTX-I, HA, and TIMP-1 with
meaningful effect sizes at week 8 and week 26 in osteoarthritic dogs.
The longer follow-up period at week 26 (roughly equivalent to 3 human years) aims to provide
data on the long-term durability of effect of iPPS compared to placebo on structural and molecular
biomarkers.
PARA_OA_008 Synovial Fluid Biomarker Study
Paradigm’s PARA_OA_008 clinical trial has now met the primary endpoint and delivered positive
clinical data at both Day 56 and Day 168. The trial demonstrated both symptomatic relief through
reduction in pain and improvement in function and additionally showed structural improvement
as measured by molecular and structural biomarkers associated with OA disease progression.
Highlights from Day 168 top-line data released during the June quarter include:
•
Structural changes in several disease features as measured by MRI were consistent with
potential DMOAD activity in iPPS-treated participants compared to placebo. Most notably,
iPPS demonstrated:
o 21% improvement in mean cartilage loss score compared to 4% worsening in the
placebo group,
o Statistically significant reductions in bone marrow lesions compared to placebo,
and
o Reduction of marginal osteophytes compared to an increase in the placebo group.
•
Reductions in molecular biomarkers of cartilage degradation (C2C, CTX II, COMP, ARGS)
were observed in iPPS-treated subjects compared to placebo control. Following discussions
with a leading expert in the research of predictive biomarkers and their role in OA
progression, it was suggested that these four biomarkers be highlighted during discussions
with the key regulatory agencies.
•
Durable clinical responses were reported out to Day 168 for twice-weekly iPPS compared
to placebo control in Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) index scores for pain, function, stiffness, and overall. The placebo group
reported using rescue medication on an average of 23 days compared to an average of only
5 days in the twice-weekly iPPS group. This comparison is highly relevant as rescue
medication was not permitted prior to Day 56, as per the clinical protocol.
Mucopolysaccharidosis (MPS I and VI)
MPS I: During the June quarter, the open-label MPS I trial was completed, and data analysed. The
primary objective of the study was to evaluate safety and tolerability of iPPS over an initial 48week treatment period, with a 6-month treatment extension available, in patients treated with
the current standard of care. Secondary and exploratory endpoints included examining the effects
of iPPS on pain, function, and quality of life, pharmacokinetics, and biomarkers of inflammatory
processes.
Paradigm reported top-line results on 6 June that the MPS I clinical trial met the primary and
secondary endpoints. No serious adverse events were reported out to week 73 and iPPS showed
meaningful improvements in pain, function, and activities of daily living and an overall
improvement in quality of life.
MPS VI: During the quarter, Paradigm reported on 13 June that the final participant had been
enrolled in the phase 2 trial based in Brazil. This placebo-controlled, double-blind, and randomised
24-week study compares iPPS to placebo in participants with the ultra-rare disease MPS VI, with
Dr Roberto Giugliani as Principal Investigator. The primary objective of the study is to evaluate the
safety and tolerability of iPPS in subjects with MPS VI at 6, 12, and 24 weeks. Throughout the study,
multiple safety reviews have been completed by the safety monitoring physician allowing
enrolment of participants aged 5 and over into the study.
Conferences
BIO International Convention 2023: Paradigm Senior Management attended and conducted a
sponsored presentation at the BIO International Convention in Boston from June 5–8. Paradigm’s
Managing Director, Mr. Paul Rennie, Chief Medical Officer Dr. Donna Skerrett, and Chief Scientific
Officer, Dr. Ravi Krishnan were in attendance to present Paradigm’s clinical development program
and conduct 1x1 meetings in conjunction with Plexus Ventures, Paradigm’s Business Development
Consultant.
Outlook
•
Paradigm has confirmed that all participants have been identified for completion of stage
1 recruitment of the PARA_OA_002 clinical trial. Once all participants in stage 1 (n=468)
are randomised and reach the pre-specified Day 84 timepoint, the DMC will recommend
the optimal dose for proceeding to stage 2 (n=468). Following dose selection, which is
expected early in Q1 CY2024, stage 2 and the PARA_OA_003 confirmatory trial (n=700) can
commence.
•
12-month clinical outcome data from the PARA_OA_008 phase 2 clinical study is expected
to be reported in late Q3 CY2023. Paradigm expects to report change from baseline in
WOMAC pain, function, and stiffness data along with patient global impression of change
(PGIC) measurements following iPPS treatment compared to placebo at the Day 365 time
point.
•
The clinical, MRI, and molecular biomarker data produced from the phase 2 PARA_OA_008
clinical trial—along with the data from the canine OA model—will be presented to the US
and EU regulatory authorities (FDA and EMA). The aim is to reach agreement on the
regulatory pathway for a DMOAD label extension. Paradigm’s phase 3 confirmatory clinical
trial plans to collect molecular (serum and urine) and structural (MRI) biomarker data in
addition to the clinical data required for the WOMAC pain and function, primary and
secondary endpoints, respectively. Paradigm plans for the meeting with the US FDA to take
place in Q4 CY2023.
•
Top-line data from the phase 2, double-blinded and randomised MPS VI clinical trial is
expected during Q4 CY2023. Participants in the study are dosed weekly for 24 weeks with
the primary endpoint being safety, followed by secondary endpoints of improvements in
pain and function.
•
Paradigm has estimated that the FY23 R&D Tax Incentive Scheme refund will equal
approximately $6.3m. This is anticipated to be received in the December 2023 quarter.
About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by
a purpose to improve patients’ health and quality of life by discovering, developing, and delivering
pharmaceutical therapies. Paradigm’s current focus is developing iPPS for the treatment of
diseases where inflammation plays a major pathogenic role, indicating a need for the antiinflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and
mucopolysaccharidosis (phase 2).
Forward Looking Statements
This Company announcement contains forward-looking statements, including statements
regarding anticipated commencement dates or completions dates of preclinical or clinical trials,
regulatory developments, and regulatory approval. These forward-looking statements are not
guarantees or predictions of future performance, and involve known and unknown risks,
uncertainties and other factors, many of which are beyond our control, and which may cause
actual results to differ materially from those expressed in the statements contained in this
presentation. Readers are cautioned not to put undue reliance on forward-looking statements.
Authorised for release by the Paradigm Board of Directors.
FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd.
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Paradigm Biopharmaceuticals Limited
ABN
Quarter ended (“current quarter”)
94 169 346 963
30 June 2023
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
-
23
(16,148)
(46,953)
-
-
(c) advertising and marketing
(83)
(470)
(d) leased assets
(15)
(85)
(e) staff costs
(423)
(2,740)
(f)
(577)
(3,306)
-
-
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
(b) product manufacturing and operating
costs
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
145
950
1.5
Interest and other costs of finance paid
(3)
(16)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
7,405
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
(17,104)
(45,192)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date (12
months)
$A’000
Proceeds from disposal of:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
65,988
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
(3,765)
-
-
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings (lease liabilities)
(24)
(104)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (Limited recourse loan repaid under
ESP)
228
416
3.10
Net cash from / (used in) financing
activities
204
62,535
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
73,203
39,721
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(17,104)
(45,191)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.3
Current quarter
$A’000
Net cash from / (used in) investing activities
(item 2.6 above)
Year to date (12
months)
$A’000
-
-
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
204
62,535
4.5
Effect of movement in exchange rates on
cash held
76
(685)
4.6
Cash and cash equivalents at end of
period
56,379
56,379
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5.2
Call deposits
5.3
Bank overdrafts
5.4
Other (provide details)
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
56,379
73,203
56,379
73,203
Current quarter
$A'000
73
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(17,104)
8.2
Cash and cash equivalents at quarter end (item 4.6)
56,379
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
-
$A’000
56,379
3.3
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
..31 July 2023.................................................................................
Authorised by: ...By the board................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover